Latest Aumake (ASX:AUK) News

Aumake Limited reported a sharp 45% drop in half-year revenue alongside a 24% increase in net loss, while securing new capital and a major distribution deal to support its pivot in the China market.

Aumake Limited has secured a four-year exclusive global distribution agreement with EZZ Life Sciences, targeting $10 million in sales and expanding its footprint in high-margin nutraceuticals.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

AuMake Limited reports positive operating cashflow and a strategic pivot into China’s high-growth OTC medicine market, supported by a $1.5 million capital raise and significant governance reforms.

Aumake Limited has obtained a Hong Kong pharmaceutical wholesale licence, enabling it to launch up to five online over-the-counter medicine stores targeting Chinese consumers. This strategic move positions the company to tap into China’s rapidly expanding OTC market.

Aumake Limited has raised $1.5 million through a share placement to strengthen inventory and expand its footprint in China, signaling renewed growth ambitions under a refreshed board.

Aumake Limited reported a near-breakeven quarter with strong cash receipts and launched a new health product brand while securing a strategic partnership to expand Australian agricultural exports to China.

Aumake Limited has partnered with Chinese conglomerate Sinomach Hainan to develop a large-scale premium hay supply chain in Australia, aiming to meet China's growing demand for high-quality forage.

Aumake Limited has launched Bio-Basic Ergothioneine, marking the debut of its innovative capital-light incubation model aimed at scaling premium health brands with minimal upfront investment.

Aumake Limited reported a strong 54% jump in revenue to nearly $40 million for FY25, while cutting its net loss by 45%. The company’s strategic pivot to higher-margin products and key distribution deals set the stage for an ambitious FY26.

Aumake Limited reported a remarkable 213% surge in quarterly cash receipts, driven by exclusive distribution agreements and strategic cost reductions, setting the stage for profitability in FY26.

Aumake Limited reports a robust 50% revenue increase to $39 million for FY25, driven by improving China-Australia trade relations. The company unveils a strategic pivot and corporate restructuring to sharpen its focus on profitable growth and brand incubation.